AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05077215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
Study NCT05077215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
Study NCT05077215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
Study NCT05077215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
Study NCT05977413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAC Notification
Description: Patient-Clinician CAC Notification. The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.
Study NCT05977413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinician Guideline Reminder
Description: The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
Study NCT04742634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC-C
Description: * DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.
Study NCT04742634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyeloSeq-HD
Description: -Laboratory test developed at Washington University School of Medicine
Study NCT04742634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyeloSeq-HD
Description: -Laboratory test developed at Washington University School of Medicine
Study NCT06340685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
Study NCT04991402 — intervention group
Intervention type: DEVICE
Intervention: Dolutegravir-based antiretroviral therapy
Description: This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care.
Study NCT06211179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Mavacamten intact oral capsule
Description: Specified dose on specified days
Study NCT06211179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Mavacamten open capsule in suspension
Description: Specified dose on specified days
Study NCT06211179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Description: Specified dose on specified days
Study NCT04943744 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Entero-tracker
Description: Esophageal STRING test (Entero-tracker)
Study NCT04943744 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: omalizumab
Description: Used in the parent study
Study NCT04943744 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dupliumab
Description: Used in the parent study
Study NCT05899257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Training using EYME
Description: Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
Study NCT05666323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Text Messaging (TM1)
Description: Receives single text message
Study NCT05666323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Description: Receive phone calls from trained MAPS counselors
Study NCT05666323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Text Messaging (TM+)
Description: Receives multiple scheduled text messages
Study NCT04694534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serious game
Description: The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions.
Study NCT04694534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Usual HAS care
Description: The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
Study NCT06573996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TENS Device
Description: Description: The active TENS device, specifically the Dental Pain Eraser (DPE), is applied to the gums for about 2.5 minutes. This intervention is designed to modulate nerve activity to reduce pain during orthodontic alignment and leveling.~Arms Associated:~Arm 1: Upper Right Side - Active TENS Device Arm 3: Lower Right Side - Active TENS Device
Study NCT06573996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intervention 2: Placebo/Sham Device
Description: The placebo/sham device is identical in appearance to the TENS device but does not deliver electrical stimulation. It is applied to the gums for 2.5 minutes to serve as a control.~Arms Associated:~Arm 2: Upper Left Side - Placebo/Sham Device Arm 4: Lower Left Side - Placebo/Sham Device
Study NCT05520034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: The participants received a 45mins, face-to-face group health education after enrollment and during the 6th month by a RA nurse. Participants received the same health education over the phone call if the patient and family caregiver could not come for any reason. They also received a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
Study NCT06007872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac Echocardiography (ICE)
Description: ICE will be used to guide trans-septal puncture and to guide device implant.
Study NCT05420935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IgG group
Description: Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml
Study NCT05420935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IgE group
Description: Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a bone marrow sampling
Study NCT05420935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IgG group + IgE group
Description: * a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml~* a bone marrow sampling
Study NCT06098469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions
Description: 10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
Study NCT05356702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Health Assessment
Description: Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
Study NCT05844501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Ondansetron 8 mg orally twice daily for 28 days
Study NCT05844501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo orally twice daily for 28 days
Study NCT05758116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg d1,q21d\*17
Study NCT04977375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
Study NCT04977375 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy
Description: Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
Study NCT04977375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Standard of care surgical resection of tumor on Day 10-28
Study NCT06537726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Description: Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
Study NCT05724277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A 15-minute mindfulness meditation will be conducted by the meditation instructor researcher.
Study NCT05724277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A 10-minute virtual reality experience will be provided by using virtual reality glasses.
Study NCT06522906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Strengthening
Description: Patients will be offered five video consultations (30-45 minutes each) with a physical therapist over 3 months. The physical therapist will prescribe an exercise program individualized to the OA patient that will include strengthening exercises (2 quadriceps, 1 hip/gluteal, 1 hamstrings/gluteal, 1 calf, and 1 other) to be performed at home 3x/week.
Study NCT06522906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Physical Activity
Description: The general program will consist of four 60-minute live video consultations conducted by a promotora. The first three sessions will be conducted every 2 weeks, with a booster session occurring one month later. The promotora will help dyads set achievable personalized physical activity goals.
Study NCT06522906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Administered by a promotora, treatment will include 4 live video educational sessions about OA
Study NCT06522906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Administered by a promotora, treatment will include 4 live video educational sessions about OA
Study NCT05831774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention - Intraosseous (IO) administration of vancomycin
Description: * IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus
Study NCT05831774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control - Standard IV administration of vancomycin
Description: Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
Study NCT05317403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venetoclax
Description: Dose Level 0: Day 1 60 mg/m2 PO x1, Days 2-14 120 mg/m2/dose PO once daily (Max: 200 mg/day)~Dose level 1: Day 1 120 mg/m2 PO x1, Days 2-14 240 mg/m2/dose PO once daily (Max: 400 mg/day)~Dose level 2: Day 1 180 mg/m2 PO x1, Days 2-14 360 mg/m2/dose PO once daily (Max: 600 mg/day)
Study NCT05317403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitadine
Description: 75 mg/m2/dose IV once daily over 15 minutes
Study NCT05317403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vorinostat
Description: 1 year to 17.99 years old: 180 mg/m2/dose PO once daily~≥18 years old 200 mg PO BID. Doses should be separated by 12 hr (±4 hr)
Study NCT05317403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: 2000 mg/m2/dose IV once daily over 3 hours~IT Cytarabine:~1. - 1.99 years old: 30 mg~2. - 2.99 years old: 50 mg~   * 3 years old: 70 mg
Study NCT05317403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 30 mg/m2/dose IV once daily over 30 minutes
Study NCT05317403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: 5 microgram/kg/dose subcutaneous (or IV over 15-30 min) once daily
Study NCT04072783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI,DTI, functional MRI
Description: 1. Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~2. Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~3. Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4.
Study NCT06517160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedBook Portal
Description: Intervention Group (With MedBook Portal \&amp; MedBook Portal Notice)~1. MedBook Portal Notice in front of the patient home-based medical card~2. Discharge prescriptions are uploaded into MedBook Portal and can be retrieved by doctors \&amp; pharmacists.~MedBook portal (https://aplikasi.jknsarawak.moh.gov.my/medbook) is a webpage that enable sharing of patient medication records among healthcare facilities under Ministry of Health. Sarawak State Health Department owned and managed this portal. All the information is kept under their server. Doctors in the Health Clinics and Study Pharmacists will be given access to this portal whereby each of the healthcare providers shall log in using their Identification Number and the password created by them. Doctor shall log in to MedBook Portal to check on discharge medication list when reviewing the patient at health clinic. MedBook Portal can be accessed both using a smartphone or a computer.
Study NCT05127044 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diffuse Reflectance Spectroscopy
Description: DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.
Study NCT05127044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BiliChek
Description: BiliChek will be used as a control for determining bilirubin content.
Study NCT05823948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Icodec
Description: Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.
Study NCT06244433 — intervention group
Intervention type: GENETIC
Intervention: whole genome sequencing
Description: Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants
Study NCT05498883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Score completion
Description: completion of the SRI score
Study NCT06601608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal therapy
Description: rosemary extract gel is used for the first time as a local drug delivery as an adjunct to non-surgical periodontal therapy in management of stage III periodontitis patients.
Study NCT06601608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug
Description: a placebo gel will be applied in deep pockets (\&gt;5mm) in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy
Study NCT06590636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expressive touching
Description: Woman's anxiety level was measured with the State-Trait Anxiety Inventory scale Following these measurements, expressive touching that lasted 15-20 minutes was performed in the following manner.~The hands of the expressive touching performer warmed to body temperature (should not be cold).~The woman's hand close to the performer was placed between the hands of the expressive touching performer.~The woman's palm was gently grasped with the palms of the expressive touching performer.~The hand below was fixed and the upper part of the woman's hand was gently rubbed with the hand above.~Before and after massaging, the woman's arms and shoulders were touched at intervals.~During the procedure, the woman was called by her name, and verbal communication with the woman was continued by holding her hands firmly and sincerely as if a handshaking done.~Before the woman's discharge from the center, her anxiety level was measured with the State-Trait Anxiety Inventory scale
Study NCT06586060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung ultrasound guided fluid balance strategy
Description: Lung ultrasound (LUS) guided fluid management based on B-Line score assessment using LUS within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first~In patients with BLS = 0-14, a zero fluid balance (FB) will be targeted if no signs of shock are present. In patients with BLS ≥ 15, a daily negative FB of -250 to -1000 mL will be targeted until BLS drops under 15. To reach daily targeted FB, furosemide-induced diuresis and RRT will be used In case of shocked patients with BLS \&amp;amp;lt; 15: they will receive fluid boluses and packed RBCs to achieve a Hb of 10 and a MAP of \&amp;amp;gt;65 mmHg.~In case of shocked patients with BLS ≥ 15: they will start norepinephrine infusion to reach a MAP of \&amp;amp;gt;65 mmHg.
Study NCT06586060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care guided fluid balance strategy
Description: fluid balance management will be guided to maintain an adequate intravascular volume while minimising weight gain within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first. Various parameters will be used to attain this goal based on case-by-case clinical judgment: lung sounds, heart rate, blood pressure, temperature, urine output, lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values To reach daily targeted fluid balance, furosemide-induced diuresis and RRT will be used
Study NCT06587009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Description: Received shock wave therapy 7 times a week and functional exercise therapy intervention
Study NCT06587009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional conservative treatment
Description: Conventional conservative treatment and functional exercise were given
Study NCT06602076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHO (Empowering Our Community & Health Outcomes)
Description: Additive intervention design wherein study participants receive remotely-delivered standard smoking cessation support (i.e., behavioral support plus nicotine replacement therapy) and engage in sexual and/or gender minoritized (SGM)-serving volunteer activities.